Abstract
According to evolving guidelines, candidates for HIV preexposure prophylaxis (PrEP) include HIV-uninfected men who have sex with men who engage in condomless anal intercourse, individuals in HIV-serodifferent sexual relationships, those with frequent anogenital sexually transmitted infections, and those who have received repeated nonoccupational postexposure prophylaxis treatment courses. In the real-world setting, indications for PrEP and management of PrEP candidates and patients may be less than clear-cut. Factors to be considered when assessing candidacy for PrEP and maximizing efficacy of treatment are discussed. This article summarizes a presentation by Demetre C. Daskalakis, MD, MPH, at the IAS-USA continuing education program held in Los Angeles, California, in April 2014.
MeSH terms
-
Adenine / administration & dosage
-
Adenine / analogs & derivatives
-
Adenine / therapeutic use
-
Anti-HIV Agents / administration & dosage*
-
Anti-HIV Agents / therapeutic use
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Deoxycytidine / therapeutic use
-
Emtricitabine
-
Female
-
HIV Infections / drug therapy
-
HIV Infections / prevention & control*
-
HIV Infections / transmission
-
Homosexuality, Male
-
Humans
-
Male
-
Organophosphonates / administration & dosage
-
Organophosphonates / therapeutic use
-
Practice Guidelines as Topic
-
Pre-Exposure Prophylaxis*
-
Risk-Taking
-
Sexual Behavior
-
Sexual Partners
-
Sexually Transmitted Diseases / drug therapy
-
Sexually Transmitted Diseases / prevention & control
-
Sexually Transmitted Diseases / transmission
-
Tenofovir
-
United States
Substances
-
Anti-HIV Agents
-
Organophosphonates
-
Deoxycytidine
-
Tenofovir
-
Emtricitabine
-
Adenine